ArticleFrontiers in medicine2025
Multidimensional predictive model for assessing clinical activity in thyroid eye disease.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Choroidal medium-large vascular index: a novel OCTA biomarker for assessing activity in thyroid eye disease.Eye (London, England) · 2026Article
- Development and validation of a nomogram for predicting non-response to tocilizumab in thyroid eye disease: a retrospective study.BMC ophthalmology · 2026Article
- SPECT/CT imaging in thyroid eye disease: an emerging role in assessing sub-clinical activity.Frontiers in ophthalmology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Thyroid eye disease (TED) is an autoimmune disorder with complex inflammatory activity that remains challenging to assess accurately. Current method, mainly the Clinical Activity Score (CAS), exhibits limitations in objectivity and comprehensiveness. This study aimed to develop a multidimensional predictive model integrating clinical parameters, SPECT/CT imaging data, and serum biomarkers, to improve TED activity evaluation. Methods: This retrospective research included 36 TED patients (72 eyes) diagnosed by EUGOGO criteria who underwent SPECT/CT examination. The Clinical Activity Score (CAS) was used to evaluate inflammatory activity. Variables with significant associations with CAS-defined activity were identified using univariate analysis, and Bayesian shrinkage regression (BSR) and the least absolute shrinkage and selection operator (LASSO) were utilized for variable selection in the primary cohort. Predictive models were constructed and evaluated using receiver operating characteristic (ROC) curves (internally validated via five-fold cross-validation), decision curve analysis (DCA), and calibration curves. Results: Five predictive models were constructed. The comprehensive Model 4, combining clinical, imaging [EX, maximal SPECT/CT uptake ratio (URmax)], and serum biomarkers (TRAb, RBC), achieved superior diagnostic accuracy (AUC: 91.18%; sensitivity: 0.91; specificity: 0.86). Model 5, retaining variables significant in univariate and multivariate analyses, demonstrated robust performance (AUC: 85.97%) with superior stability during cross-validation (ROC mean: 0.8417). Key predictors included male sex (OR = 11.74), TRAb levels, EX, URmax, and RBC count. SPECT/CT-derived URmax correlated strongly with disease activity, while serum biomarkers complemented imaging limitations. Conclusion: Multidimensional integration of clinical, imaging, and biomarker data significantly enhances TED activity evaluation compared to single-modality approaches. The multidimensional model offers superior diagnostic accuracy, addressing the limitations of conventional methods. These findings advocate for a holistic approach in TED management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.